CASI Pharmaceuticals, Inc. (CASI)
CASI Stock Price Chart
Explore CASI Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze CASI price movements and trends.
CASI Company Profile
Discover essential business fundamentals and corporate details for CASI Pharmaceuticals, Inc. (CASI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Jun 1996
Employees
233.00
CEO
Wei-Wu He
Description
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
CASI Financial Timeline
Browse a chronological timeline of CASI Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 14 May 2026
Upcoming earnings on 12 Nov 2025
Earnings released on 29 Aug 2025
Earnings released on 16 May 2025
EPS came in at -$0.69 falling short of the estimated -$0.61 by -13.11%, while revenue for the quarter reached $6.24M , missing expectations by -0.95%.
Earnings released on 31 Mar 2025
EPS came in at -$0.79 falling short of the estimated -$0.60 by -31.67%, while revenue for the quarter reached $13.36M , beating expectations by +80.63%.
Earnings released on 15 Nov 2024
EPS came in at -$0.55 surpassing the estimated -$0.62 by +11.29%, while revenue for the quarter reached $7.79M , beating expectations by +70.90%.
Earnings released on 16 Aug 2024
EPS came in at -$0.52 surpassing the estimated -$0.63 by +17.46%, while revenue for the quarter reached $3.98M , missing expectations by -10.18%.
Earnings released on 14 May 2024
EPS came in at -$0.71 falling short of the estimated -$0.05 by -1.32K%, while revenue for the quarter reached $3.41M , missing expectations by -71.59%.
Earnings released on 28 Mar 2024
EPS came in at -$0.29 falling short of the estimated -$0.24 by -20.83%, while revenue for the quarter reached $6.09M , missing expectations by -35.28%.
Earnings released on 14 Nov 2023
EPS came in at -$0.35 surpassing the estimated -$0.56 by +37.50%, while revenue for the quarter reached $8.84M , missing expectations by -6.08%.
Earnings released on 11 Aug 2023
EPS came in at -$0.77 falling short of the estimated -$0.50 by -54.00%, while revenue for the quarter reached $9.82M , missing expectations by -2.68%.
Earnings released on 26 Apr 2023
EPS came in at -$1.44 falling short of the estimated -$0.64 by -125.00%, while revenue for the quarter reached $8.35M , missing expectations by -8.27%.
Earnings released on 29 Mar 2023
EPS came in at -$0.40 falling short of the estimated -$0.37 by -8.11%, while revenue for the quarter reached $15.26M , beating expectations by +41.42%.
Earnings released on 14 Nov 2022
EPS came in at -$0.38 surpassing the estimated -$0.51 by +25.49%, while revenue for the quarter reached $10.21M , beating expectations by +3.05%.
Earnings released on 12 Aug 2022
EPS came in at -$0.56 surpassing the estimated -$0.65 by +13.85%, while revenue for the quarter reached $8.57M , beating expectations by +8.91%.
Stock split effective on 2 Jun 2022
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2022
EPS came in at -$0.60 surpassing the estimated -$1.00 by +40.00%, while revenue for the quarter reached $9.06M , missing expectations by -1.96%.
Earnings released on 28 Mar 2022
EPS came in at -$0.40 surpassing the estimated -$0.60 by +33.33%, while revenue for the quarter reached $9.16M , beating expectations by +0.89%.
Earnings released on 12 Nov 2021
EPS came in at -$0.70 falling short of the estimated -$0.60 by -16.67%, while revenue for the quarter reached $8.11M , beating expectations by +7.79%.
Earnings released on 12 Aug 2021
EPS came in at -$0.50 surpassing the estimated -$0.90 by +44.44%, while revenue for the quarter reached $7.16M , beating expectations by +18.94%.
Earnings released on 13 May 2021
EPS came in at -$1.10 falling short of the estimated -$0.50 by -120.00%, while revenue for the quarter reached $5.74M , beating expectations by +13.58%.
Earnings released on 30 Mar 2021
EPS came in at -$1.20 falling short of the estimated -$0.70 by -71.43%, while revenue for the quarter reached $4.82M .
Earnings released on 9 Nov 2020
EPS came in at -$1.40 falling short of the estimated -$0.60 by -133.33%, while revenue for the quarter reached $4.24M .
CASI Stock Performance
Access detailed CASI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.